Elsevier

Neurobiology of Aging

Volume 17, Issue 5, September–October 1996, Pages 707-716
Neurobiology of Aging

Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: The role of the complement system

https://doi.org/10.1016/0197-4580(96)00113-3Get rights and content

Abstract

This review discusses key findings indicating potential roles of the complement (C)-system in chronic inflammation in Alzheimer's disease (AD) brain. Although there is no means to cure or prevent the disease, recent studies suggest that antiinflammatory drugs may delay the onset of AD dementia. One target of these drugs may be the (C)-system, which is best known for its roles in inflammatory processes in peripheral tissues. However, recent data show C-system expression and regulation in brain cells, and C-system protein deposition in AD plaques. It is still unclear whether C-system activation contributes to neuropathology in the AD brain, as shown in multiple sclerosis (MS). New clinical studies with antiinflammatory agents are now under general consideration by the Alzheimer's Disease Cooperative Study program. In this review I outline research directions which address possible C-system contributions to neurodegeneration. Finally, I discuss potential pharmacological interventions designed to control segments of classical inflammatory cascades in which the C-system is highly implicated. These aspects are critical to the understanding of C-mediated responses in normal and pathologic brain.

References (157)

  • T.C. Farries et al.

    Evolution of the complement system

    Immunol. Today

    (1991)
  • D.G. Fraser et al.

    C5a/C5a des-arg-induced increase in blood pressure in the guinea pig: Role of thromboxane

    Immunopharmacology

    (1990)
  • M. Fratelli et al.

    Role of clusterin in cell adhesion and death mechanisms in P19 embryonic carcinoma cells

    Biochem. Biophys. Acta

    (1996)
  • S. Haga et al.

    Synthetic Alzheimer amyloid beta/A4 peptides enhance production of C3 component by cultured microglial cells

    Brain Res.

    (1993)
  • T. Ishii et al.

    Complement, microglial cells and amyloid fibril formation

    Res. Immunol.

    (1992)
  • D.E. Jenne et al.

    Clusterin the intringuing guises of a widely expressed glycoprotein

    Trends Biochem. Sci.

    (1992)
  • S. Johnson et al.

    Complement mRNA in mammalian brain: Responses to Alzheimer's disease and experimental brain lesioning

    Neurobiol. Aging.

    (1992)
  • S.A. Johnson et al.

    Perforant path transection induces complement C9 deposition in hippocampus

    Exp. Neurol.

    (1996)
  • M.Z. Kounnas et al.

    Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin

    J. Biol. Chem.

    (1995)
  • M.Z. Kounnas et al.

    LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted β-amyloid precursor protein and mediated its degradation

    Cell

    (1995)
  • M. Lampert-Etchells et al.

    Sulfated glycoprotein-2 is increased in rat hippocampus following entorhinal cortex lesioning

    Brain Res.

    (1991)
  • N.J. Laping et al.

    TGFβ-1 induces neuronal and astrocyte genes: Tubulin alpha-1, glial fibrillary acidic protein and clusterin

    Neuroscience

    (1994)
  • L. Liu et al.

    Complement and clusterin in the spinal cord dorsal horn and gracile nucleus following sciatic nerve injury in the adult rat

    Neuroscience

    (1995)
  • U. Lucca et al.

    Nonsteroidal anti-inflammatory drug use in Alzheimer's disease

    Biol. Psychiatry

    (1994)
  • P.C. May et al.

    Sulfated glycoprotein 2: New relationships of this multifunctional protein to neurodegeneration

    Trends Neurosci.

    (1992)
  • P.L. McGeer et al.

    Activation of the classical complement pathway in brain tissue of Alzheimer patients

    Neurosci. Lett.

    (1989)
  • P.L. McGeer et al.

    Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain

    Mol. Brain Res.

    (1991)
  • P.L. McGeer et al.

    Distribution of clusterin in Alzheimer brain tissue

    Brain Res.

    (1992)
  • P. Monk et al.

    The role of protein kinase C activation and inositol phosphate production in the regulation of cell-surface expression of MAC-1 by complement fragment C5a

    Biochem. Biophys. Acta

    (1991)
  • Y. Namba et al.

    Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and Kuru plaque amyloid in Creutzfeldt-Jacob disease

    Brain Res.

    (1991)
  • T. Oda et al.

    Purification and characterization of brain clusterin

    Biochem. Biophys. Res. Commun.

    (1994)
  • T. Oda et al.

    Clusterin (apoJ) alters the aggregation of amyloid β-peptide (Aβ-42) and forms slowly sedimenting Aβ complexes that cause oxidative stress

    Exp. Neurol.

    (1995)
  • M.W. Oliver et al.

    The protease inhibitor leupeptin interferes with the development of LTP in hippocampal slices

    Brain Res.

    (1989)
  • M.G. O'Sullivan et al.

    Lipopolysaccaride priming of alveolar macrophages for enhanced synthesis of prostanoids involves induction of a novel prostaglandin H synthase

    J. Biol. Chem.

    (1992)
  • G.M. Pasinetti et al.

    Transforming growth factor β1 (TGF-β1) and fibronectin mRNA in rat brain: Response to injury and cell-type localization

    Neuroscience

    (1993)
  • G.M. Pasinetti et al.

    Sulfated glycoprotein 2 (SGP-2) mRNA is expressed in rat striatal astrocytes following ibotenic acid lesions

    Neurosci. Lett.

    (1991)
  • L. Raij et al.

    Renal injury in DOCA-salt sensitive hypertensive C5-sufficient and C5-deficient mice

    Kidney Int.

    (1989)
  • S.B. Abramson et al.

    The mechanisms of action of non-steroidal anti-inflammatory drugs

    Arthritis Rheum.

    (1989)
  • P.S. Aisen et al.

    Inflammatory mechanisms in Alzheimer's disease: Implications for therapy

    Am. J. Psychol.

    (1994)
  • K. Andersen et al.

    Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam study

    Neurology

    (1995)
  • A. Auteri et al.

    Action of a new non-steroidal antiinflammatory drug, nimesulide, on activation of the complement system: an in vitro study

    Intern. J. Tissue React.

    (1988)
  • X. Bi et al.

    Calpain-mediated regulation of AMPA receptors in adult rat brain

    Neuroreport

    (1994)
  • C.D. Breder et al.

    Distribution and characterization of cyclooxygenase immunoreactivity in the ovine brain

    J. Comp. Neurol.

    (1992)
  • J.C.S. Breitner et al.

    Inverse association of anti-inflammatory treatments and Alzheimer's disease. Initial results of a co-twin control study

    Neurology

    (1994)
  • B. Brugg et al.

    Inflammatory processes induce β-amyloid precursor protein changes in mouse brain

  • V. Casolaro et al.

    Nimesulide, a sulfonamide nonsteroidal anti-inflammatory drug, inhibits mediator release from human basophils and mast cells

    J. Pharmacol. Exp. Ther.

    (1993)
  • J.W. Chang et al.

    Quantification of the IL-1β induced messages, plasminogen activation inhibitor type-1 and prostaglandin G/H synthase-2 in Alzheimer's disease

    Soc. Neurosci. Abstr.

    (1994)
  • J.W. Chang et al.

    Localization of inducible prostaglandin G/H synthase-2 (cyclooxygenase-2, PGHS-2) to neurons in Alzheimer's and control human brain

    Soc. Neurosci. Abstr.

    (1995)
  • N.H. Choi et al.

    A serum SP40,40 modulates the formation of membrane attack complex of complement on erythrocytes

    Mol. Immunol.

    (1989)
  • N.H. Choi-Miura et al.

    SP-40,40 is a constituent of Alzheimer's amyloid

    Acta Neuropathol.

    (1992)
  • Cited by (109)

    • Mesenchymal stem cell-mediated immunomodulation in cell therapy of neurodegenerative diseases

      2018, Cellular Immunology
      Citation Excerpt :

      This interaction has been shown to stimulate microglial phagocytosis [10]. In a genetically modified animal model that C3 was inhibited, Aβ accumulation and neuronal degeneration were enhanced compared with the control group [11]. Similarly, elevated mRNA levels of complement components have been found in affected brain regions in animal models of PD [12].

    • Age-Related Macular Degeneration-Associated Genes in Alzheimer Disease

      2015, American Journal of Geriatric Psychiatry
      Citation Excerpt :

      It was suggested that C3 had a protective role against AD, perhaps by mediating opsonization and facilitating phagocytosis of amyloid centrally or peripherally. Complement may prevent β-amyloid build-up or reduce hippocampal excitotoxicity.37 If apoptosis contributes to AD then complement activity may facilitate clearance of cellular fragments.

    • Immunity and Alzheimer's disease: Immunological perspectives on the development of novel therapies

      2013, Drug Discovery Today
      Citation Excerpt :

      Moreover, production of C5a results in activation of mitogen-activated protein kinase (MAPK) [24]. Animals genetically deficient for C5 were found to be more susceptible to excitotoxins [25]. Furthermore, mice expressing soluble Crry (a rodent Creg with inhibitory activities on complements similar to CD46 and CD55) had a significant increase in Aβ accumulation and neuronal degeneration [26].

    View all citing articles on Scopus
    View full text